Hypothesis

Real‑time modulation of OSK expression based on circulating senescence‑associated secretory phenotype (SASP) levels and cell‑free DNA methylation yields a wider therapeutic window for partial reprogramming than fixed‑dose cyclic regimens.

Rationale

Transient OSK exposure resets epigenetic age within a 10‑13 day window before dedifferentiation or senescence rebound occurs 1 2.

In heterogeneous tissues the optimal duration varies because local SASP concentrations influence TET enzyme activity and DNA methylation dynamics; high SASP sustains a methylated state that blunts reprogramming efficacy and pushes cells toward a senescent rebound after day 15. Conversely, clearing senescent cells lowers SASP, reduces inhibitory cytokines (IL-6, IL-1β, TNF-α) and permits more complete demethylation of age‑associated loci without triggering pluripotency programs.

Mechanistic Insight

SASP factors activate NF‑κB signaling, which recruits DNMT1 to chromatin and opposes TET‑mediated oxidation of 5‑mC. When OSK is present, TET enzymes initiate demethylation at pluripotency‑associated enhancers; however, persistent NF‑κB signaling can stall this process, leading to incomplete epigenetic resetting and accumulation of cells expressing low levels of OCT4 without full pluripotency—a state that predisposes to dedifferentiation if OSK exposure continues. Intermittent senolytic clearance (e.g., navitoclax‑loaded nanoparticles) timed to the rising edge of SASP biomarkers would lower NF‑κB activity, allowing TET enzymes to finish demethylation cycles before OSK is withdrawn.

Testable Prediction

In aged mice carrying a doxycycline‑inducible OSK cassette and a SASP‑responsive reporter (e.g., p16‑Il2‑Luc), an algorithm that initiates OSK pulses when plasma IL-6 drops below a tissue‑specific threshold and terminates them when cfDNA methylation age shows a 20 % reduction will produce:

• A greater cumulative decrease in epigenetic age across liver, spleen and muscle after 8 weeks compared to a standard 2‑day‑on/5‑day‑off schedule.
• Lower sustained OCT4/Nanog expression (measured by immunostaining and RNA‑scope).
• Improved functional readouts (grip strength, wound closure) without increase in teratoma incidence.

Experimental Design

Four groups (n=15 each):

• (A) fixed cyclic OSK (2 days on/5 days off)
• (B) OSK plus continuous senolytic (navitoclax‑NP)
• (C) adaptive OSK guided by SASP reporter luminescence
• (D) control (no OSK)

Measure plasma IL-6, cfDNA methylation (Horvath mouse clock), tissue‑specific OCT4/Nanog, SA‑β‑gal, and fibrosis markers at weeks 2, 4, 6, 8. Statistical analysis via two‑way ANOVA with post‑hoc Tukey.

Falsifiability

If adaptive OSK does not outperform fixed cycling in epigenetic age reduction, or if it increases OCT4/Nanog persistence or teratoma formation, the hypothesis is refuted. Conversely, a significant improvement in rejuvenation metrics coupled with a dedifferentiation marker suppression would support the mechanistic link between SASP clearance, TET activity, and safe epigenetic resetting.